Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
For people with type 2 diabetes receiving concomitant insulin or sulfonylureas, there is a theoretical risk of hypoglycaemia based on class experience with GLP-1-based therapies
Across the SURPASS 1-5 trials involving over 6,000 participants, the incidence of adjudicated pancreatitis was low and comparable to control groups
10.2337/db09-1694
But they may last for up to 20 weeks if you move up to the highest dosage
US$ 27.70
US$ 26.66
US$ 29.38
US$ 25.04
US$ 24.70
US$ 24.32
US$ 26.78
US$ 25.05
